The company focuses on destabilizing oncoprotein targets using direct ligand-induced degradation, upstream regulators, protein orphaning, and proteome susceptibility mapping. Cedilla's small-molecule therapeutics target key cancer drivers and other life-threatening diseases outside of oncology. The company's approach is based on a new dimension of precision oncology that selectively inhibits oncogenic drivers with small molecules that modulate proteins in their functional state. Cedilla's conditional inhibitors are unlocking critical and elusive cancer targets, including TEAD and CDK2. The company is patient-focused and has a driven team.